Qualitätsbericht 2022 48 | 70 Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperationspartner / Sponsor A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis (GS-US-418-3899) Gastroenterologie Prof. Dr. med. Frank Seibold Galapagos A long-term Extension Study to Evaluate the Safety of Filgonitib in Subjects with Ulcerative Colitis (Gilead GS-US-418-3899) Gastroenterologie Prof. Dr. med. Frank Seibold Gilead Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgonitib in the Induction and Maintenance of Remission in Subject with Moderately to Severely Active Crohn’s Disease (Gilead_GS-US-419-3895_MC) Gastroenterologie Prof. Dr. med. Frank Seibold Gilead A Long-Term Extension Study to Evaluate the Safety of Filgonitib in Subjects with Crohn’s Disease (Gilead_GS-US-419-3896_MC_OL) Gastroenterologie Prof. Dr. med. Frank Seibold Gilead A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn’s Disease (ETRO_144) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann-La Roche / Genentech An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III (ETRO_145) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann-La Roche / Genentech An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies (ETRO_951) Gastroenterologie Prof. Dr. med. Frank Seibold Hoffmann-La Roche / Genentech A low-interventional, prospective multi-center study to evaluate real-world clinical, biochemical and patient-reported responses to tofacitinib induction therapy in patients with moderately to severly active ulcerative colitis in Switzerland (KIC Start) Gastroenterologie Prof. Dr. med. Frank Seibold Pfizer Real-world non-Interventional, prospective, observational Study to describe real-world treatment patterns in patients on vedolizumab treatment, for moderate to severe active Crohn or Ulcerative Colitis Gastroenterologie Prof. Dr. med. Frank Seibold Takeda SLC7-mediated amino acid transport across the materno-fetal barrier: association to human disease Gynäkologie und Geburtshilfe Dr. med. Ruedi Moser-Hässig Institut für Biochemie und Molekulare Medizin der Universität Bern Revisiting the steroidogenic pathways in human placenta and primary human trophoblast cells Gynäkologie und Geburtshilfe Dr. med. Ruedi Moser-Hässig Institut für Biochemie und Molekulare Medizin der Universität Bern Materno-fetal transport of iron: association with human gestational diseases Gynäkologie und Geburtshilfe Dr. med. Ruedi Moser-Hässig Institut für Biochemie und Molekulare Medizin der Universität Bern Patienten- sicherheit Behandlungs- qualität Messungen im Überblick Patienten- zufriedenheit Qualitätsstrategie Lehre und Forschung Kontinuierliche Verbesserungen
RkJQdWJsaXNoZXIy MzQxOTE=